Pharmaceutical Technology

APRIL 5, 2023

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

Development 130

Development Bioinformatics Drugs Immune Response 130

Scienmag

JULY 12, 2021

Scientists have produced the first fine-detail molecular blueprints of a bacterial enzyme known as Lit, which is suspected to play a “stealthy” role in the progression of infection by reducing the immune response.

Immune Response 75

Immune Response Scientist Development Drugs 75

XTalks

APRIL 1, 2025

We are thrilled with the results from the EQUATOR study, which mark a major milestone in the development of itolizumab as a first-line treatment option for aGVHD, said Bruce Steel, CEO of Equillium, in the companys news release.

Immune Response 94

Immune Response Trials Licensing Licensing 94

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. for serogroup W to 20.5

Vaccination 195

Vaccination Vaccine Immune Response Bacteria 195

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

Pharmaceutical Technology

FEBRUARY 6, 2023

Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections. Feinstein Institutes Institute of Molecular Medicine professor Dr Wang said: “Sepsis is a complex and fatal complication.

Protein 263

Protein Research Antibody Immune Response 263

Pharmaceutical Technology

APRIL 28, 2023

Biotechnology company Therini Bio has raised $36m in a Series A financing round to develop fibrin-targeted therapies to treat neurodegenerative and retinal diseases. THN391 binds the inflammation-driving component of fibrin, known for activating the immune responses in neurodegenerative and ophthalmologic diseases.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

Camargo

DECEMBER 13, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. One common characteristic for most if not all biologics is the triggering of an immune response or anti-drug antibodies.

Development 161

Development Production Immune Response Licensing 161

Drug Patent Watch

DECEMBER 9, 2024

The Role of Analytical Characterization Analytical characterization is a critical step in the development of biosimilars. Additionally, the immunogenicity of biosimilars, which is the ability of the drug to trigger an immune response, can be highly variable and impact the safety and efficacy of the drug. References Bilea, A.

Clinical Trials 97

Clinical Trials Clinical Trials Immune Response Production 97

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. When people think about innovation drivers in global healthcare, they often think of “big pharma,” and not necessarily companies in the plasma medicines space.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

Pharmaceutical Technology

FEBRUARY 3, 2023

The failure of several late-stage trials highlights the challenging nature of HIV vaccine development. Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

XTalks

FEBRUARY 5, 2025

Avtozma is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist that works by targeting specific inflammatory proteins to dampen immune responses. Avtozma was submitted for regulatory approval to the FDA in January 2024 and the European Medicines Agency (EMA) in February 2024.

FDA Approval 102

FDA Approval Marketing Antibody Immune Response 102

pharmaphorum

JULY 18, 2022

It then elicits an immune response against that spike protein. You have a response with immunoglobulins type G (antibodies) and robust cellular response with both CD4 and CD8 T-cells being activated,” Morgon states. We get a higher immune response with the inhaled compared to the injectable,” Morgon relays.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

Scienmag

APRIL 1, 2021

Early life exposure to antibotics in utero and through mother’s milk disrupts beneficial gut bacteria, compromising T-cell development, Rutgers research shows Exposure to antibiotics in utero and infancy can lead to an irreversible loss of regulatory T-cells in the colon-a valuable component of the immune system’s response toward allergens (..)

Immune Response 75

Immune Response Allergies Bacteria Development 75

The Pharma Data

JULY 29, 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Immune Response 52

Immune Response Development Medicine Drugs 52

Pharmaceutical Technology

MAY 10, 2023

Gilead Sciences stated that the two programmes have the potential to address a number of indications and to provide development opportunities both alone and along with its wider portfolio. The financial terms of the deal were not disclosed by the companies.

Immune Response 130

Immune Response DNA Clinical Trials Clinical Trials 130

pharmaphorum

MARCH 4, 2021

UK chancellor Rishi Sunak has announced a budget loaded with initiatives designed to kick-start the UK’s economy as it recovers from the coronavirus pandemic, with vaccine development, pharma and life sciences playing a key role. The post Budget 2021: Sunak focuses on vaccine development to restart economy appeared first on.

Vaccination 105

Vaccination Vaccine Development Life Science 105

Scienmag

SEPTEMBER 21, 2020

September 21, 2020–(BRONX, NY)–The first study comparing the immune responses of adults and children with COVID-19 has detected key differences that may contribute to understanding why children usually have milder disease than adults. The study was published today in Science […].

Immune Response 48

Immune Response Vaccination Vaccine Development 48

Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. They are often used to mimic or enhance natural biological processes, such as immune responses. Their small size allows them to distribute widely throughout the body.

Development 97

Development Drugs Immune Response Manufacturing 97

Scienmag

JUNE 3, 2021

Strong immune responses to unchanging, conserved parts of the 2009 H1N1 pandemic flu virus suggest strategies for effective universal vaccines Credit: Guthmiller et al.

Immune Response 98

Immune Response Vaccination Vaccine Development 98

Pharmaceutical Technology

DECEMBER 16, 2022

In a recent paper in Nature Medicine by Mackensen and colleagues, a CD19 CAR-T cell therapy was successfully used to treat five patients with refractory SLE. The example of rituximab, originally a cancer drug, now used for lupus, has shown the potential of adopting cancer medications for lupus.

Immune Response 147

Immune Response Marketing Antibody Trials 147

STAT News

DECEMBER 13, 2022

Medicines that reshape or tamp down immune responses may be life-changing for patients with cancer and autoimmune disorders, but in some cases they can awaken a dormant virus and unleash a deadly brain disease. A new study suggests that the root of the problem is buried in our genetic code. Read the rest…

Genetics 105

Genetics Immune Response Gene Drugs 105

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Better access to high-quality data makes informed decision-making easier and promotes innovation in vaccine development.

Vaccination 97

Vaccination Vaccine Development Marketing 97

Pharmaceutical Technology

MAY 29, 2023

Novavax has received positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for full marketing authorisation (MA) of its Covid vaccine, Nuvaxovid (NVX-CoV2373) , in the European Union (EU). The safety and efficacy of Nuvaxovid was evaluated as a primary series.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

pharmaphorum

SEPTEMBER 30, 2020

This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market. As expected, patients in the study formed two populations: those who had already mounted an immune response and those whose immune response was not yet adequate.

Antibody 135

Antibody Immune Response Trials Protein 135

pharmaphorum

JANUARY 15, 2021

Johnson & Johnson’s Janssen pharma unit is further behind in the development of its vaccine, which has the crucial advantage of being administered in a single shot. Data on durability of immune responses in trial participants aged over 65 years will be available in late January and longer-term follow-up to one year is planned.

Vaccination 119

Vaccination Vaccine Immune Response Antibody 119

pharmaphorum

JULY 5, 2021

The reason none of them can say with certainty whether or not they are truly safe is because everyone’s immune response is unique to that individual. In some cases, we see significant variations among similarly aged people with similar health histories when it comes to their individual responses to the virus or vaccines.

Immune Response 105

Immune Response Antibody Vaccination Vaccine 105

Medical Xpress

DECEMBER 19, 2022

Northwestern Medicine scientists have identified a new therapeutic target for tumors and developed a compound which slowed tumor growth and bolsters immune responses in mice, according to research published in Science Advances.

Immune Response 71

Immune Response Scientist Medicine Development 71

Scienmag

DECEMBER 9, 2020

Scientists have developed the first poliovirus […].

Immune Response 75

Immune Response Vaccination Vaccine Scientist 75

Scienmag

JANUARY 18, 2021

Novel tuberculosis vaccine demonstrated strong immune response in mice Credit: University of Sydney Scientists in Australia have developed a method for the rapid synthesis of safe vaccines, an approach that can be used to test vaccine strategies against novel pandemic pathogens such as SARS-CoV-2, the virus that causes COVID-19.

Vaccination 93

Vaccination Vaccine Immune Response Scientist 93

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) Global Head, Janssen Research & Development, Johnson & Johnson. Additional follow-up with trial participants is currently underway.

Immune Response 52

Immune Response Vaccination Medicine Vaccine 52

Pfizer

JULY 19, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. has a fever.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

XTalks

AUGUST 26, 2020

The anti-inflammatory macrophages help in preventing an immune response from becoming dangerous, as seen with patients with autoimmune disease. This helps to ensure that inflammation naturally subsides after the initial immune response and promotes tissue repair.

Bacteria 105

Bacteria Immune Response Protein Medicine 105

pharmaphorum

DECEMBER 9, 2021

The long-acting antibody combination, formerly known as AZD7442 (tixagevimab and cilgavimab) has been cleared for pre-exposure prophylaxis (PrEP) of COVID-19 in adults and adolescents aged 12 and older who weigh at least 40kg and have compromised immunity. The antibody is also under a rolling review in the EU.

Antibody 124

Antibody Immune Response Vaccination Vaccine 124

Worldwide Clinical Trials

JUNE 21, 2024

Currently, there are 12 approved ADC drugs, and several hundred more are in the development pipeline. Four distinct challenges were discussed at ASCO involving ADC development, including: Target Expression Levels : The targeted antigen must be sufficiently expressed on tumor cells.

Antibody 162

Antibody Clinical Trials Clinical Trials In-Vitro 162

pharmaphorum

AUGUST 5, 2022

MiroBio was formed in 2019 to develop checkpoint agonist antibodies for autoimmune and inflammatory disorders that can be used to apply the “natural brakes” of the immune system. 7 integrin, with three candidates in early-stage clinical development.

Antibody 105

Antibody Immune Response Development Medicine 105